Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUY922 in Myelofibrosis and Refractory PV/ET
NCT01668173Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2012
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Luminespib in primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocythemia (ET), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2012; status: terminated.
02
Drugs
Luminespib
03
Conditions
primary myelofibrosis (PMF)polycythemia vera (PV)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT01668173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01668173.